Phathom Pharmaceuticals (PHAT) Price & Analysis

Compare

524 Followers

PHAT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.21 - $19.50

Previous CloseN/A

Volume285.74K

Average Volume (3M)1.21M

Market Cap

$823.66M

Enterprise Value$1.12B

Total Cash (Recent Filing)$212.31M

Total Debt (Recent Filing)$203.56M

Price to Earnings (P/E)―

Beta1.93

Next Earnings

Nov 06, 2025

EPS Estimate

-0.47

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.05

Shares Outstanding70,943,710

10 Day Avg. Volume1,409,916

30 Day Avg. Volume1,211,169

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.36

Enterprise Value/Revenue13.68

Enterprise Value/Gross Profit15.86

Enterprise Value/Ebitda-4.07

Forecast

1Y Price Target

$21.67

Price Target Upside99.91% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Financial PerformancePHAT reported $39.5M in 2Q25 Voquezna revenue, which was 9% above the FactSet consensus.

Prescription Growth29.3K unique healthcare providers wrote filled prescriptions through mid-July reflecting a 24% increase since last quarter’s update.

Revenue GrowthThe company has demonstrated sequential revenue growth while utilizing strategic cost reductions.

Bears Say

Market ValuationPHAT's current market cap is considered to undervalue Voquezna's revenue potential.

Phathom Pharmaceuticals News

Phathom appoints Sanjeev Narula as chief financial, business officer

Phathom Pharmaceuticals (PHAT) announced the appointment of Sanjeev Narula as Chief Financial and Business Officer. Narula most recently...

3d ago

PHAT

Phathom Pharmaceuticals Appoints New Chief Financial Officer

Phathom Pharmaceuticals ( ($PHAT) ) has provided an announcement. On October 6, 2025, Phathom Pharmaceuticals appointed Sanjeev Narula...

3d ago

PHAT

Phathom clarifies no reduction in lead shareholder’s ownership amid 13D filing

Phathom Pharmaceuticals (PHAT) clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be...

2M ago

PHAT

Phathom Pharmaceuticals’ Earnings Call Highlights Growth and Challenges

Phathom Pharmaceuticals, Inc. (($PHAT)) has held its Q2 earnings call. Read on for the main highlights of the...

2M ago

PHAT

Phathom Pharmaceuticals Reports Strong Q2 Growth

Phathom Pharmaceuticals, Inc. ( ($PHAT) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

PHAT

Phathom Pharmaceuticals: Strong Buy Rating Driven by Robust Revenue Performance and Growth Potential

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Phathom Pharmaceuticals, with a...

2M ago

PHAT

Phathom Pharmaceuticals reports Q2 EPS (79c), consensus (89c)

Reports Q2 revenue $39.5M, consensus $35.58M. “The second quarter marked a significant step forward in Phathom’s journey toward...

2M ago

PHAT

Phathom Pharmaceuticals sees 2025 revenue $165M-$175M, consensus $159.4M

07:27 EDT Phathom Pharmaceuticals (PHAT) sees 2025 revenue $165M-$175M, consensus $159.4M Published first on TheFly – the ultimate...

2M ago

PHAT

Avidity, Phathom mentioned as potential takeout targets at Needham

Needham, in a research note to investors on the biotech industry, mentioned Avidity (RNA) and Phathom Pharmaceuticals (PHAT)...

3M ago

BMY

NVO

Phathom Pharmaceuticals appoints Anne Marie Cook as CLO, corporate secretary

Phathom Pharmaceuticals (PHAT) announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary....

4M ago

PHAT

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Chime Financial, Inc. (CHYM)...

4M ago

RKT

BLNK

Phathom Pharmaceuticals Gains FDA Exclusivity for VOQUEZNA

Phathom Pharmaceuticals ( ($PHAT) ) has provided an update. On June 16, 2025, Phathom Pharmaceuticals announced that the...

4M ago

PHAT

Phathom Pharmaceuticals announces FDA correction to Orange Book Listing

Phathom Pharmaceuticals (PHAT) announced that the U.S. Food and Drug Administration, FDA, has updated the Approved Drug Products...

4M ago

PHAT

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Beyond Meat (BYND) 86.64%...

4M ago

RDW

ALMS

PHAT FAQ

What was Phathom Pharmaceuticals’s price range in the past 12 months?

Phathom Pharmaceuticals lowest stock price was $2.21 and its highest was $19.50 in the past 12 months.

What is Phathom Pharmaceuticals’s market cap?

Phathom Pharmaceuticals’s market cap is $823.66M.

When is Phathom Pharmaceuticals’s upcoming earnings report date?

Phathom Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 28 days.

How were Phathom Pharmaceuticals’s earnings last quarter?

Phathom Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.95 by -$0.1.

Is Phathom Pharmaceuticals overvalued?

According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Phathom Pharmaceuticals pay dividends?

Phathom Pharmaceuticals does not currently pay dividends.

What is Phathom Pharmaceuticals’s EPS estimate?

Phathom Pharmaceuticals’s EPS estimate is -0.47.

How many shares outstanding does Phathom Pharmaceuticals have?

Phathom Pharmaceuticals has 70,943,710 shares outstanding.

What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?

Phathom Pharmaceuticals reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.95. Following the earnings report the stock price went up 8.295%.

Which hedge fund is a major shareholder of Phathom Pharmaceuticals?

Currently, no hedge funds are holding shares in PHAT

Phathom Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

181.41%

Trailing 12-Months

Asset Growth

-21.65%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Phathom Pharmaceuticals

Phathom Pharmaceuticals (PHAT) is a biopharmaceutical company focused on developing and commercializing innovative therapies for gastrointestinal diseases. The company primarily targets conditions such as peptic ulcer disease and gastroesophageal reflux disease (GERD) with its lead product candidate, Vonoprazan, a novel potassium-competitive acid blocker designed to provide improved efficacy and tolerability compared to traditional therapies. Phathom operates in the pharmaceuticals sector, emphasizing research, development, and potential commercialization of medications that enhance patient outcomes in digestive health.

Phathom Pharmaceuticals (PHAT) Earnings & Revenues

Historic Earnings Reports

PHAT Company Deck

PHAT Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects strong growth in prescription numbers and revenue, successful cost management, and a positive resolution regarding product exclusivity. However, there are potential challenges with supply disruptions and Medicare coverage. The strategic focus on gastroenterologists is expected to drive further growth.View all PHAT earnings summaries

PHAT Stock 12 Month Forecast

Average Price Target

$21.67

▲(99.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","29":"$29","8.75":"$8.75","15.5":"$15.5","22.25":"$22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8.75,15.5,22.25,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.85,13.092307692307692,14.334615384615384,15.576923076923077,16.819230769230767,18.06153846153846,19.303846153846152,20.546153846153842,21.788461538461537,23.03076923076923,24.27307692307692,25.515384615384612,26.757692307692302,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.85,12.605384615384615,13.36076923076923,14.116153846153846,14.871538461538462,15.626923076923077,16.38230769230769,17.13769230769231,17.893076923076926,18.64846153846154,19.403846153846153,20.15923076923077,20.914615384615388,{"y":21.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.85,12.246153846153845,12.642307692307693,13.038461538461538,13.434615384615384,13.830769230769231,14.226923076923077,14.623076923076923,15.01923076923077,15.415384615384616,15.811538461538461,16.20769230769231,16.603846153846156,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.43,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.52,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.27,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.12,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >